Ringer Lactate - Roztwór do infuzji Polonia - poloneză - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

ringer lactate - roztwór do infuzji

baxter polska sp. z o.o. - natrii chloridum + kalii chloridum + calcii chloridum dihydricum + sodu mleczan - roztwór do infuzji - -

Solutio Ringeri Lactate Fresenius - roztwór do infuzji Polonia - poloneză - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

solutio ringeri lactate fresenius - roztwór do infuzji

fresenius kabi polska sp. z o.o. - calcii chloridum,kalii chloridum,natrii chloridum,natrii lactas - roztwór do infuzji - -

Płyn Ringera z mleczanami Fresenius - Roztwór do infuzji Polonia - poloneză - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

płyn ringera z mleczanami fresenius - roztwór do infuzji

fresenius kabi polska sp. z o.o. - natrii chloridum + kalii chloridum + calcii chloridum dihydricum + natrii lactas - roztwór do infuzji - -

Ultomiris Uniunea Europeană - poloneză - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinuria, paroksysmal - selektywne leki immunosupresyjne - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Aspaveli Uniunea Europeană - poloneză - EMA (European Medicines Agency)

aspaveli

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuria, paroksysmal - leki immunosupresyjne - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.